Vanguard Group Inc
- SEC CIK
- 0000102909
- Latest filing
- Jan 29, 2026
PTIX holding history
Protagenic Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PTIX overviewAll 13F holders of PTIXFull Q4 2025 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −33,166−100.0% | Sold out | Holders |
| Q1 2025 | 33,166 | $6.47K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2024 | 33,166 | $16.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 33,166 | $21.1K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 33,166 | $30.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 33,166 | $58.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 33,166 | $32.8K | <0.1% | +215+0.7% | Added | Holders |
| Q3 2023 | 32,951 | $60.6K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 32,951 | $66.9K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 32,951 | $57.0K | <0.1% | −26,126−44.2% | ReducedConverted for a 1-for-4 split | Holders |
| Q4 2022 | 236,309 | $94.5K | <0.1% | −16,516−6.5% | Reduced | Holders |
| Q3 2022 | 252,825 | $145.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 252,825 | $183.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 252,825 | $206.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 252,825 | $350.0K | <0.1% | +121,310+92.2% | Added | Holders |
| Q3 2021 | 131,515 | $246.0K | <0.1% | +110,732+532.8% | Added | Holders |
| Q2 2021 | 20,783 | $60.0K | <0.1% | +20,783 | New | Holders |